Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WuXi Celebrates First $100 Million Quarter; Sinovac Reports 50% Revenue Increase; SciClone Not Worried About Zydaxin Cuts: China Earnings Round Up (Part 1)

This article was originally published in PharmAsia News

Executive Summary

China's major players rack up double-digit growth in the second quarter, with WuXi PharmaTech celebrating its first $100 million quarter and Sinovac seeing a 50% increase in revenues. On the heels of the NovaMed acquisition, SciClone Pharmaceuticals Inc. is preparing to enter more markets in China and anticipates price cuts for its flagship product Zadaxin. In a recurring feature, PharmAsia News combs through earnings calls to bring readers the highlights in the critical emerging markets.

You may also be interested in...



Global Mechanism Needed To Monitor And Boost Use Of Influenza Vaccines, Particularly In Asia - Study

Although there is a visible uptrend in seasonal influenza vaccination, few countries reach recommended targets, IFPMA study finds.

From Biologics To Corporate Venture, China's Leading CRO Continues To Evolve

In an effort to boost its biological capabilities and continue its march into additional integrated services, China's leading contract research organization WuXi PharmaTech has acquired Abgent Inc., a provider of biological research agent products and services

From Biologics To Corporate Venture, China's Leading CRO Continues To Evolve

In an effort to boost its biological capabilities and continue its march into additional integrated services, China's leading contract research organization WuXi PharmaTech has acquired Abgent Inc., a provider of biological research agent products and services

Related Content

UsernamePublicRestriction

Register

LL1126230

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel